Vedolizumab

• FirST lines of biologics in pAtients with ulceRaTivE colitis: a Randomised controlled trial Pending
  2024-514964-24-00 Phase III 1 country University Hospital Of Clermont-Ferrand
• IMPACT OF ANTI-TNF, VEDOLIZUMAB AND TOFACITINIB ON AORTIC STIFFNESS, CAROTID INTIMA-MEDIA THICKNESS AND CARDIOVASCULAR RISK OF PATIENTS WIT… Pending
  2024-517314-15-00 Phase III/IV 1 country Centre Hospitalier Universitaire Amiens Picardie
• Fecal microbiota transplantation in patients receiving infliximab and vedolizumab for ulcerative colitis: A randomized controlled trial Pending
  2024-520373-12-00 Phase IV 1 country Varsinais-Suomen hyvinvointialue
• Vedolizumab Subcutaneous Long-term Open-label Extension Study in Pediatric Subjects Recruiting
  2023-508804-39-00 Phase III 10 countries Takeda Development Center Americas Inc.
• A Phase 2a Study of the Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Co… Recruiting
  2024-520201-39-00 Phase II 7 countries Odyssey Therapeutics Inc.
• SILVER-study Recruiting
  2024-517502-28-01 Phase IV 1 country Amsterdam UMC Stichting
• Phase 3 Study of Vedolizumab Subcutaneous in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease Recruiting
  2023-503188-40-00 Phase III 10 countries Takeda Development Center Americas Inc.
• Efficacy and Safety of Vedolizumab Intravenous in Pediatric Chronic Pouchitis Recruiting
  2023-504773-20-00 Phase III 8 countries Takeda Development Center Americas Inc.
• MOVE-IT Recruiting
  2024-517123-39-00 Phase IV 1 country Odense University Hospital
• SIMBA Recruiting
  2024-514740-82-00 Phase IV 1 country Stichting Amsterdam UMC
• A Study to Compare the Efficacy and Safety of Vedolizumab With and Without Upadacitinib in Adults With Moderately to Severely Active Crohn's… Recruiting
  2023-509391-42-00 Phase III/IV 18 countries Takeda Development Center Americas Inc.
• Evaluation of the efficacy and safety of dual biologic and/or small molecule therapy in patients with induction-resistant ulcerative colitis… Recruiting
  2023-506628-98-00 Phase II 1 country Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy
• Evaluation of the efficacy and safety of dual biological therapy in patients with refractory Crohn's disease resistant to induction (FLAMING… Recruiting
  2023-506626-37-00 Phase II 1 country Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy
• Evaluating the safety of shortened infusion tiMes for dIfferent oNcological immUnoThErapies; An observational prospective study Recruiting
  2024-518878-14-01 Phase IV 1 country Isala Klinieken Stichting
• This is a multicenter, double-blind, randomized study to compare the safety, effectiveness and immunogenicity (level and body resistance to … Recruiting
  2023-509775-16-00 Phase II 1 country Instytut Pomnik Centrum Zdrowia Dziecka
• A Study to Evaluate Whether Healing all Bowel Wall Layers is a Superior Treatment Target in Patients with Active Crohn’s Disease (CD). Recruiting
  2023-509096-16-00 Phase IV 8 countries Alimentiv Inc.
• Comparison of Vedolizumab treatment to Adalimumab dose intensification in Crohn’s disease patients with loss of response or biomarker activi… Recruiting
  2023-508154-25-00 Phase IV 1 country Centre Hospitalier Universitaire De Saint Etienne
• A Long-term Study in Children and Teenagers with Ulcerative Colitis or Crohn’s Disease treated with Vedolizumab IV Recruiting
  2023-509046-36-00 Phase III 6 countries Takeda Development Center Americas Inc.
• Prevention of postoperative endoscopic disease recurrence in Crohn’s disease: a multicentric study that compares the systematic start of bio… Recruiting
  2022-500311-39-00 Phase IV 2 countries UZ Leuven
• A study of Vedulizumab in Children and Teenagers with Moderate to Severe Crohn's Disease (CD) Recruiting
  2023-509045-13-00 Phase III 6 countries Takeda Development Center Americas Inc.
• A Study to Compare Risankizumab to Vedolizumab in Adult Subjects With Moderate to Severe Ulcerative Colitis Ended
  2024-518998-33-00 Phase III 20 countries AbbVie Deutschland GmbH & Co. KG
• A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis. Ended
  2023-507705-34-00 Phase III 11 countries Alvotech Swiss AG
• A study in people with moderately to severely active ulcerative colitis to see how well an investigational treatment called PB016 works and … Ended
  2022-502778-18-00 Phase III 7 countries Polpharma Biologics S.A.
• A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC) Ended
  2023-509018-12-00 Phase III 6 countries Takeda Development Center Americas Inc.

Showing 1–24 of 27 trials